Market evolution: Human vaccines excluding SARS (CN 30024190) — 2015–2025

Introduction

This report analyses the evolution of the European Union's trade in human vaccines (excluding those for SARS-related coronaviruses) over the period from 2015 to 2025. The EU is a major global player in the production and export of vaccines, a critical sector for public health. Using official trade data, this analysis examines trends in trade value, volume, and geographical distribution to identify the key dynamics shaping the market. The period covers pre-pandemic trends, the significant disruption and scaling efforts during the COVID-19 era, and the subsequent market adjustments, offering a comprehensive view of a strategically important industry. Full data and further details can be explored on the EU Trade Dashboard for product 30024190.

A Structural Shift in the EU's Trade Balance

The period from 2022 to 2025 reveals a significant structural shift in the EU's trade dynamics for human vaccines. While the EU has maintained a massive trade surplus, its magnitude has begun to narrow, primarily due to a sharp contraction in export value, even as imports grew steadily.

Export Value Contraction Overrides Stable Volumes

Between the first and last years of the detailed dataset, the total value of EU vaccine exports decreased by 5.2%, from €15.17 billion to €14.38 billion. This occurred despite a smaller 4.0% decline in the quantity exported (from 9,958 to 9,563 tonnes). The unit export price also saw a minor decline of 1.3%. The most dramatic change was the peak-to-trough movement: exports surged to a maximum of €19.32 billion in an intermediate year before falling sharply, indicating a volatile post-pandemic adjustment. The full trend can be viewed on the general trade overview.

Import Growth Narrows the Trade Surplus

In contrast to exports, EU imports of vaccines grew substantially in value, rising by 35.9% to reach €3.68 billion by 2025. Import volumes grew more modestly (6.3%), indicating that higher prices drove the increase, with the unit import price climbing by 27.6%. As a result, the EU's trade surplus narrowed by 14.1%, falling from €12.46 billion to €10.70 billion. This dynamic highlights a growing reliance on external suppliers, albeit from a position of dominant strength.

Summary of EU Vaccine Trade Performance (2022 vs. 2025)

High Concentration and Shifting Partnerships

The EU's vaccine trade is highly concentrated, both in terms of which EU members dominate exports and which foreign partners are most significant. This concentration presents both strategic advantages and potential vulnerabilities.

Belgian Dominance and Divergent EU Member Trends

Within the EU, trade is heavily skewed. For exports, Belgium is the undisputed leader, with its exports growing by 8.7% to €8.75 billion, accounting for over 60% of total EU exports by 2025. Conversely, the Netherlands saw its exports plummet by 61.4%. On the import side, the Netherlands and Belgium remained the top importers, with Belgium seeing explosive growth (+467%). Specialisation data for 2025 confirms Ireland and Belgium as having the highest Revealed Symmetric Comparative Advantage (RSCA) in vaccine production.

A Persistent US Anchor Amidst Volatile Partners

The United States remains the EU's single most important trading partner for vaccines by a wide margin. US exports to the EU grew by 36.1% to €3.09 billion, while EU exports to the US saw more modest growth of 6.9%, reaching €6.94 billion. A dramatic story is the collapse of EU exports to China, which fell by 91.2% from €2.61 billion to just €230 million. Meanwhile, other markets like Singapore (+1,066%) and Mexico (+113.2%) saw extraordinary, albeit more volatile, growth. This volatility is reflected in high coefficient of variation (CV) scores for partners like China (CV=1.78) and Singapore (CV=1.17).

High Import Concentration Signals Dependency Risk

The Herfindahl-Hirschman Index (HHI) for imports by value remained high, rising from 7,098 to 7,561, indicating a concentrated import market heavily reliant on a few key suppliers, primarily the US. The HHI for exports was lower but also increased by 11.8%, suggesting some consolidation in export destinations as well.

The EU's Evolving Strategic Position in the Global Vaccine Market

Despite the recent dip in export performance, the overarching data confirms the EU's role as a global vaccine powerhouse. Key vulnerability and trade intensity metrics show an economy deeply integrated into and dominant within the global vaccine supply chain.

Unambiguous Net Exporter with Growing Export Intensity

The EU's net import reliance was deeply negative throughout the period, averaging around -142% in 2022, meaning exports vastly outstripped imports. While this figure worsened to -997% in 2025, this is a statistical reflection of the changing ratio between a shrinking surplus and a small import base, not a sign of newfound dependency. More telling are the export propensity and trade intensity metrics. Both surged, with export propensity rising by 88.7% to 131.7% and trade intensity increasing by 73.2% to 126.1% by 2025. This indicates that an ever-larger share of EU vaccine production is destined for international markets.

Production Capacity Underpins Trade Dominance

The EU's trade position is built on a substantial industrial base. EU production value stood at €13.22 billion in the latest available year. While this represents a 29.6% decrease from a peak of €18.79 billion, it underscores that the vast majority of vaccines traded by the EU are produced domestically. This strong production foundation provides resilience and explains the persistently large trade surplus.

Conclusion

The EU's market for human vaccines (excl. SARS) between 2015 and 2025 is characterised by consolidation and strategic importance. While the post-2022 period has seen a correction from pandemic-era peaks, with export values falling and the trade surplus narrowing, the EU's fundamental position remains robust. It is a highly specialised, net-exporting region whose vaccine trade is deeply integrated into the global economy, particularly with the United States. High concentration in both production (led by Belgium) and in import sourcing presents efficiency benefits but also highlights dependency risks. The rising export propensity and trade intensity metrics signal that the EU's vaccine industry is, and is likely to remain, fundamentally oriented towards serving global markets.